Figure 4 shows that treating CKD rats either with β,γ-meATP or MDP significantly inhibited the mRNA upregulation of the osteo-/chondrogenic marker gene Sox9, as compared with vehicle-treated CKD rats, while no differences between groups were observed for the early osteo-/chondrogenic marker gene Alpl (encoding TNAP). This evidence concerns the gene ALPL and chronic kidney disease.